0000000001078689

AUTHOR

C Imbimbo

showing 5 related works from this author

Efficacy and safety of Cyprofloxacin XR 1000mg once daily versus Ciprofloxacin 500mg twice daily in the treatment of complicated urinary tract infect…

2009

The aim of this trial was to compare the efficacy and safety of extended-release ciprofloxacin (CIPRO XR) versus the immediate-release formulation (CIPRO IR) in the treatment of complicated urinary tract infections (UTIs). 212 patients were randomized to CIPRO XR 1,000 mg tablet once daily or CIPROXIN IR 500 mg tablet twice daily. Treatment efficacy was evaluated by bacteriological outcome. Safety was measured by recording adverse events. The rate of bacteriological eradication was 83% in the CIPRO XR group and 75% in the CIPRO IR. the overall incidence of adverse events reported was higher in the CIPRO IR group. The authors conclude that CIPRO XR is a safe and effective treatment for compl…

cUTI ciprofloxacin XR ciprofloxacin iR antibiotics urinary tract infectionSettore MED/24 - Urologia
researchProduct

Erratum: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: Are further improveme…

2011

A new edition of the TNM was recently released that includes modifications for the staging system of kidney cancers. Specifically, T2 cancers were subclassified into T2a and T2b (10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers. OBJECTIVE: Our aim was to validate the recently released edition of the TNM staging system for primary tumor classification in kidney cancer. DESIGN, SETTING, AND PARTICIPANTS: Our multicenter retrospective study consisted of 5339 patients treated in 16 academic Italian centers. INTERVENTION: Patients underwent either radical or partial nephrecto…

Oncologymedicine.medical_specialtyCorrigendum to ‘‘Validation of the 2009 TNM Version in a Largebusiness.industryUrologyUrologyRenal Cell Carcinomamedicine.diseaseTNMTNM; Renal Cell CarcinomaRenal cell carcinomaInternal medicineCohortmedicinebusinesserratum error priority journal
researchProduct

VALUTAZIONE DELLA SENSIBILITà E SPECIFICITà DELLA RISONANZA MAGNETICA ENDORETTALE E DELLA ECOGRAFIA TRANSRETTALE NELLA STADIAZIONE DELL'ADENOCARCINOM…

2007

OBJECTIVES. Nowadays endorectal probes for Magnetic Resonance Imaging (MRI) have better resolutions, which allows to acquire high-level images of prostate and to improve the MRI sensitivity and specificity to determine the cancer volume and the extraprostatic extension. The objective of the present study is to evaluate the sensitivity and diagnostic accuracy of endorectal MRI for identifying the local extension of prostate carcinoma compared to transrectal sonography (TRUS) of prostate. MATERIALS AND METHODS. The study included 81 patients with clinical suspect of cancer and/or elevated values of serum prostate specific antigen (PSA), who underwent endorectal MRI with 1.5 T endorectal probe…

MRITRUS adenocarcinoma prostaticoSettore MED/24 - Urologia
researchProduct

Evaluation of an alternative dosing regimenwith tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy.

2007

AIM: To examine the preference for two dosing regimens of 20 mg of tadalafil, on demand or three times per week, in men affected with erectile dysfunction (ED) in Italy. METHODS: Scheduled Use versus on demand Regimen Evaluation (SURE) is a multicenter, crossover and open-label study, involving 94 urology centers in Italy. Patients aged 18 years or older affected with ED for at least 3 months were enrolled and randomized to 20 mg of tadalafil treatment on demand or three times per week for 5-6 weeks. After a 1-week washout, patients were crossed over to the alternate regimen for 5-6 weeks. A treatment preference question was used to determine the preferred treatment regimen. International I…

Malemedicine.medical_specialtyAlternate; Erectile dysfunction; On demand; SURE study; Tadalafil; Three times per week; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome; Nephrology; EndocrinologyPhosphodiesterase Inhibitorserectile dysfunctionUrologyerectile dysfunction; SURE study; on demand; three times per week; alternate; tadalafilon demandDrug Administration Schedulelaw.inventionSettore MED/24 - UrologiaEndocrinologyRandomized controlled triallawOn demandInternal medicinealternateMedicineHumansClinical significanceDosingthree times per weekErectile dysfunction SURE Study on demand three times per week alternate tadalafilSURE studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTadalafilSurgeryRegimenErectile dysfunctionTreatment OutcomeItalyNephrologyAlternate; Erectile dysfunction; On demand; SURE study; Tadalafil; Three times per week; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcomebusinesstadalafilmedicine.drugCarbolines
researchProduct

Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Neede…

2010

Background: A new edition of the TNM was recently released that includes modifications for the staging system of kidney cancers. Specifically, T2 cancers were subclassified into T2a and T2b ( 10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers. Objective: Our aim was to validate the recently released edition of the TNM staging system for primary tumor classification in kidney cancer. Design, setting, and participants: Our multicenter retrospective study consisted of 5339 patients treated in 16 academic Italian centers. Intervention: Patients underwent either radical or part…

MaleNephrologyOncologyIMPACTmedicine.medical_treatmentValidation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?Kidney neoplasm; Nephrectomy; Renal cell carcinoma; TNM; UrologyNephrectomyTNMCohort StudiesTNM; renal cell carcinomarenal cell carcinoma; staging systemPROPOSALKidney neoplasm; Nephrectomy; Renal cell carcinoma; TNMRenal cell carcinomaPRIMARY TUMOR CLASSIFICATIONstaging systemNEPHRECTOMYRECLASSIFICATIONkidney cancerRADICAL NEPHRECTOMYMiddle AgedKidney neoplasmPrimary tumorKidney NeoplasmsNephrectomyREVISIONclassificationCohortCUTOFFKidney neoplasm; Nephrectomy; Renal cell carcinoma; TNM; Aged; Carcinoma Renal Cell; Cohort Studies; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective StudiesFemalekidney neoplasmHumanrenal cell carcinomamedicine.medical_specialtyUrologyTNM staging systemSTRATIFICATIONInternal medicinemedicineHumansCarcinoma Renal CellAgedNeoplasm StagingRetrospective Studiesbusiness.industrykidney neoplasm; renal cell carcinoma; TNM; NEPHRECTOMYCarcinomaRenal CellRetrospective cohort studymedicine.diseaseSurgerySIZECohort StudiebusinessKidney cancerKidney diseaseEuropean Urology
researchProduct